— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —

— Exploratory clinical outcome measures showed improvements out to two years in pain, stiffness, and function across all doses and groups —

— Phase 2 ASCEND trial of PCRX-201 in knee osteoarthritis advancing with first topline read out on track for year-end 2026 —

BRISBANE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the publication of positive two-year results from its Phase 1 clinical trial evaluating PCRX-201 (enekinragene inzadenovec), the company’s investigational locally administered gene therapy for knee osteoarthritis (OA). Published in the Annals of the Rheumatic Diseases, the study showed that PCRX-201, when administered as a single local administration via intra-articular injection into the knee, was well tolerated in patients with moderate to severe knee osteoarthritis. Through two years of follow-up, exploratory outcome measures showed improvements in pain, stiffness, and function across all dose cohorts among patients who remained in the study.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.